Evaluating a new questionnaire for myositis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the validity, reliability, and responsiveness of the BETY-Biopsychosocial Questionnaire (BETY-BQ) in individuals diagnosed with myositis. The study focuses on understanding how myositis affects physical function, quality of life, and psychosocial factors such as anxiety and depression. By utilizing a comprehensive questionnaire, the research seeks to provide insights into the holistic evaluation of patients and improve disease management. Participants will be asked to complete the BETY-BQ to gather data on their experiences and challenges related to myositis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of myositis
* To be over 18 years old
* Consent of the participant

Exclusion Criteria:

* Uncontrolled/other clinically significant disease (chronic obstructive pulmonary disease, congestive heart failure, endocrine system diseases, neurological, psychological diseases, etc.) individuals with a diagnosis,
* Pregnant individuals,
* Individuals with malignancy

Where it's running

• Hacettepe University
  Ankara, Altındağ, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Orkun Tüfekçi, PT, PhD (c)
• Email: orkuntf@gmail.com
• Phone: 5319502648

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging markers for bulbar involvement in inclusion body myositis among IBM and comparison groups

  This study tests whether ultrasound and MRI can detect swallowing and bulbar muscle problems in people with inclusion body myositis.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07823101

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• Treatment Response in Myositis-Associated RP-ILD in Adults

  This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.

  Recruiting Singapore General Hospital · Singapore · NCT07775235

• Measuring muscle health with a handheld electrical impedance device (mScan)

  This project will test whether a handheld mScan device can quickly measure muscle health in adults with myopathies and in people without muscle disease by comparing its readings to MRI.

  Recruiting Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07502989

• Patient-rooted insights to shape myositis science

  This global project asks people living with myositis (and their care partners) to share experiences and rank research questions so the community can see which issues matter most.

  Recruiting Myositis International Health & Research Collaborative Alliance Foundation · New Orleans, Louisiana · NCT07374107

• AlloNK® therapy combined with rituximab for treating certain autoimmune diseases

  This study is testing if a new treatment called AlloNK® combined with rituximab can help people with tough-to-treat autoimmune diseases feel better.

  Recruiting at 52 sites Phase 2 Artiva Biotherapeutics, Inc. · Tuscaloosa, Alabama and 51 other locations · NCT06991114

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.